drugset
drugset / Trial / NCT04647916

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

NCT04647916 ↗

Phase 2 Active not recruiting 44 enrolled SWOG Cancer Research Network Gilead Sciences · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and/or extend the time until the cancer gets worse.

Timeline

Start
2021-06-08
Primary completion
2027-12-31
Completion
2028-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sacituzumab Govitecan Monoclonal antibody — Intravenous

Indications

Her2-receptor negative breast cancer female breast carcinoma invasive breast carcinoma metastatic malignant neoplasm in the brain